Colibactin-Producing Escherichia coli / E. coli pks+

Colibactin-Producing Escherichia coli / E. coli pks + could promote a procarcinogenic immune environment through impairment of antitumor T-cell response, leading to tumoral resistance to immunotherapy
Lopès et al. 2020

E. coli harboring the pathogenicity island pks (also called clb), encoding the enzymes that produce colibactin.
Pleguezuelos-Manzano et al. 2020a CANCER DISCOVERY 10: 635

Colibactin-Producing Escherichia coli / E. coli pks + are present in a substantial fraction of individuals (about 20% of healthy individuals, about 40% of patients with inflammatory bowel disease, and about 60% of patients with familial adenomatous polyposis or CRC)
Buc et al. 2013 PLoS One 8: e56964

Escherichia coli can carry the pathogenicity island Colibactin-encoding polyketide synthase (pks) (part of the genome) which encodes a set of enzymes that synthesize colibactin
Nougayrède et al., 2006 Science 313: 848-851

see also:
Colibactin & Escherichia coli (E. coli)